Horizon Therapeutics PLC (NASDAQ:HZNP) CFO Sells $1,985,284.00 in Stock

Horizon Therapeutics PLC (NASDAQ:HZNP) CFO Paul W. Hoelscher sold 70,903 shares of the business’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $28.00, for a total transaction of $1,985,284.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

HZNP stock traded down $0.49 during trading on Friday, hitting $27.19. The stock had a trading volume of 804,036 shares, compared to its average volume of 1,867,231. The company’s 50 day moving average price is $25.03 and its two-hundred day moving average price is $25.16. Horizon Therapeutics PLC has a 1-year low of $16.56 and a 1-year high of $29.44. The stock has a market cap of $5.16 billion, a price-to-earnings ratio of 14.86, a price-to-earnings-growth ratio of 1.62 and a beta of 0.88. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.12 and a current ratio of 2.20.

Horizon Therapeutics (NASDAQ:HZNP) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.14. Horizon Therapeutics had a net margin of 5.90% and a return on equity of 30.33%. The firm had revenue of $320.60 million during the quarter, compared to the consensus estimate of $296.27 million. During the same quarter in the previous year, the company posted $0.48 EPS. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. As a group, sell-side analysts forecast that Horizon Therapeutics PLC will post 1.6 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of HZNP. FMR LLC increased its stake in shares of Horizon Therapeutics by 165.1% during the 1st quarter. FMR LLC now owns 5,205,217 shares of the biopharmaceutical company’s stock valued at $137,575,000 after acquiring an additional 3,242,071 shares during the last quarter. Nuveen Asset Management LLC increased its stake in shares of Horizon Therapeutics by 1,910.0% during the 2nd quarter. Nuveen Asset Management LLC now owns 1,672,839 shares of the biopharmaceutical company’s stock valued at $40,249,000 after acquiring an additional 1,589,614 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of Horizon Therapeutics during the 1st quarter valued at about $27,663,000. Price T Rowe Associates Inc. MD increased its stake in shares of Horizon Therapeutics by 1,774.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,101,748 shares of the biopharmaceutical company’s stock valued at $26,508,000 after acquiring an additional 1,042,969 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Horizon Therapeutics by 11.4% during the 2nd quarter. Renaissance Technologies LLC now owns 8,754,275 shares of the biopharmaceutical company’s stock valued at $210,628,000 after acquiring an additional 896,500 shares during the last quarter. 86.46% of the stock is owned by institutional investors.

Several equities research analysts recently commented on HZNP shares. Citigroup upgraded shares of Horizon Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $21.00 to $32.00 in a research report on Wednesday, May 1st. Cowen set a $35.00 price objective on shares of Horizon Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 7th. BMO Capital Markets upgraded shares of Horizon Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $29.00 to $36.00 in a research report on Wednesday, August 14th. Mizuho set a $27.00 price objective on shares of Horizon Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, May 8th. Finally, BidaskClub upgraded shares of Horizon Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $32.73.

About Horizon Therapeutics

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Featured Article: What is the Quick Ratio?

Insider Buying and Selling by Quarter for Horizon Therapeutics (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.